This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Osteoporosis  • Randomized Controlled Trial  • Drug Therapy, Other  • Alert me on articles by topic

Anna M. Sawka, MD, PhD, FRCPC; Joel G. Ray, MD, MSc, FRCPC; Qilong Yi, PhD; Robert G. Josse, MBBS, FRCP; Eva Lonn, MD, MSc, FRCPC

Arch Intern Med. 2007;167(19):2136-2139.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hyperhomocysteinemia is associated with an increased risk of skeletal fractures.^1-5 For example, in a prospective cohort study of 2406 individuals from the Netherlands, the associated relative risk of fracture was 1.4 per 1-SD increase in plasma homocysteine.¹ In a US prospective study of 825 men and 1174 women, the highest quartile of plasma homocysteine concentration was associated with nearly a 4 times higher risk of hip fracture in men and 1.9 times higher risk in women compared with the lowest quartile.³ Little is known about the effect of lowering homocysteine levels on the risk of clinical fractures. We evaluated the effect of combined treatment with folic acid, pyridoxine hydrochloride (also known as vitamin B₆), and cyanocobalamin (also known as vitamin B₁₂) on the . . . [Full Text of this Article]

Methods

Study Design and Follow-up

Statistical Analyses

Results

Comment

AUTHOR INFORMATION